Last10K.com

Rexahn Pharmaceuticals, Inc. (RNN) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2012

Rexahn Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1228627 Ticker: RNN
Document and Entity Information (USD $)
 12 Months Ended
Dec. 31, 2012
Mar. 22, 2013
Jun. 30, 2012
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2012    
Entity Registrant Name REXAHN PHARMACEUTICALS, INC.    
Entity Central Index Key 0001228627    
Current Fiscal Year End Date --12-31    
Entity Filer Category Smaller Reporting Company    
Entity Common Stock, Shares Outstanding   119,428,989  
Document Fiscal Year Focus 2012    
Document Fiscal Period Focus FY    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 24,426,818

View differences made from one year to another to evaluate Rexahn Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Rexahn Pharmaceuticals, Inc..

Continue

Assess how Rexahn Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Rexahn Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheet
Balance Sheet (parenthetical)
Statement Of Cash Flows
Statement Of Comprehensive Loss
Statement Of Operations
Statement Of Stockholders' Equtiy (deficit)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (details)
Accounts Payable And Accrued Expenses (tables)
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Of Future Rental Payments) (details)
Commitments And Contingencies (schedule Of Investments Under Securities Purchase Agreement And Relo) (details)
Commitments And Contingencies (tables)
Common Stock
Common Stock (narrative) (details)
Common Stock (summary Of Allocation Of Proceeds From Offering) (details)
Common Stock (summary Of Issuances) (details)
Common Stock (tables)
Deferred Research And Development Arrangement
Deferred Research And Development Arrangement (details)
Equipment, Net
Equipment, Net (details)
Equipment, Net (tables)
Fair Value Measurements
Fair Value Measurements (reconciliation Of Changes In The Fair Value Of Liabilities) (details)
Fair Value Measurements (schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (details)
Fair Value Measurements (tables)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (schedule Of Deferred Tax Assets And Valuation Allowance) (details)
Income Taxes (tables)
Marketable Securities
Marketable Securities (details)
Marketable Securities (tables)
Note Receivable
Note Receivable (details)
Operations And Organization
Operations And Organization (details)
Other Liabilities
Other Liabilities (narrative) (details)
Other Liabilities (schedule Of Deferred Lease Incentive) (details)
Other Liabilities (tables)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (details)
Prepaid Expenses And Other Current Assets (tables)
Put Feature On Common Stock
Put Feature On Common Stock (schedule Of Anti-dilution Provision And Significant Valuation Assumptions) (details)
Put Feature On Common Stock (schedule Of Unrealized Gains Losses On Fair Value Of Anti-dilution Provision) (details)
Put Feature On Common Stock (summary Of Fair Value Of Anti-dilution Provision Recorded As Liabilities) (details)
Put Feature On Common Stock (summary Of Shares Indexed To The Anti-dilution Provision) ( Details)
Put Feature On Common Stock (tables)
Stock-based Compensation
Stock-based Compensation (narrative) (details)
Stock-based Compensation (schedule Of Assumptions Made In Calculating The Fair Value Of Options) (details)
Stock-based Compensation (summary Of Employee And Non-employee Transactions) (details)
Stock-based Compensation (summary Of Stock Compensation Expense) (details)
Stock-based Compensation (summary Of Stock Options Outstanding) (details)
Stock-based Compensation (summary Of Unvested Shares) (details)
Stock-based Compensation (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (concentrations Of Credit Risk) (details)
Summary Of Significant Accounting Policies (equipment) (details)
Summary Of Significant Accounting Policies (impairment Of Long-lived Assets) (details)
Summary Of Significant Accounting Policies (policies)
Warrants
Warrants (narrative) (details)
Warrants (schedule Of Assumptions Used In Calculating Fair Value Of Warrants) (details)
Warrants (schedule Of Fair Value Of Warrants Issued) (details)
Warrants (schedule Of Unrealized Gains Losses On Fair Value Of Warrants) (details)
Warrants (summary Of Changes In Warrants Outstanding During The Period) (details)
Warrants (summary Of Shares Indexed To The Warrants) (details)
Warrants (tables)
Ticker: RNN
CIK: 1228627
Form Type: 10-K Annual Report
Accession Number: 0001140361-13-013730
Submitted to the SEC: Fri Mar 22 2013 4:14:39 PM EST
Accepted by the SEC: Fri Mar 22 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/rnn/0001140361-13-013730.htm